Press Releases

Acer Therapeutics Receives Patents in the U.S. and EU for the use of Sodium Phenylbutyrate (NaPB) and Prodrugs for the Potential to Treat Maple Syrup Urine Disease (MSUD) The United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued U.S. Patent 9,078,865 and EU patent 2,456,304, respectively, covering ACER-001, a […]

Acer Therapeutics Closes $4.1 Million Series A Financing, Forms Board of Directors and Advances Lead Development Programs. CAMBRIDGE, MA, July 1, 2015 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, closed its Series A round with $4.1 million. Proceeds from the financing will be used […]

Acer Therapeutics Appoints Benjamin Dewees as Vice President, Regulatory Affairs and Manufacturing Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Benjamin Dewees as Vice President, Regulatory Affairs and Manufacturing. In this role, Mr. Dewees brings extensive experience in regulatory processes for, and approvals of, therapies […]

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-002 for the Potential Treatment of Vascular Ehlers-Danlos Syndrome In January 2015, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) to celiprolol […]